MedTrace Logo

Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

NCT02176187 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-07-14

No results posted yet for this study

Summary

Study to compare the effect of 'natural' as opposed to 'optimal' technique on the percentage of the dose received from the Respimat® inhaler and metered dose inhaler

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Berodual® Respimat® inhaler

fenoterol hydrobromide 50μg + ipratropium bromide 20μg

DRUG

Berodual® metered dose inhaler

fenoterol hydrobromide 50μg + ipratropium bromide 20μg

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2004-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176187 on ClinicalTrials.gov